Stimulant Overdose Learning Community

Information and Application Registration Form

Overview

Stimulant-involved overdose is an urgent and evolving public health challenge. From January 2021 through June 2024, 59.0% of overdose deaths involved stimulants, including 43.1% that involved both stimulants and opioids and 15.9% that involved stimulants alone. From 2018 to 2023, overdose death rates involving cocaine nearly doubled nationally, while rates involving psychostimulants (primarily methamphetamine) more than doubled (Tanz et al., 2025).

The National Council for Mental Wellbeing and the Centers for Disease Control and Prevention are pleased to announce the Stimulant Overdose Learning Community (LC), a national virtual learning opportunity for public health and health care practitioners.

This free learning community will help participants understand the changing landscape of stimulant use and overdose, share challenges and expertise, and identify practical actions to prevent and respond to stimulant-involved overdose in their local contexts.

The learning community will:

- Build public health and health care practitioners' knowledge of stimulant-involved overdose.
- Explore drivers of stimulant overdose.
- Discuss ways to tailor interventions to people and communities most at risk.
- Share evidence-based approaches for stimulant use management, engagement, linkage to care and retention in care.
- Clarify practical roles for public health and healthcare partners, including primary care and emergency departments.
- Create structured opportunities for participants to exchange perspectives, challenges, promising practices and locally relevant solutions.

Eligibility

Public health and health care practitioners from state, local, territorial and Tribal health departments are encouraged to apply, in addition to staff from community-based organizations (CBOs), community behavioral health organizations (CBHOs), Certified Community Behavioral Health Clinics (CCBHCs), and other health care

organizations or public health agencies, including those that focus on overdose prevention or whose participation in the LC strengthens their ability to apply learning in their local community.

Applicants should bring relevant experience, expertise or perspectives and should be prepared to apply learning within their organization or community. We strongly encourage individuals with lived experience of substance use to participate in the LC. The lived experience perspective and understanding are deeply valued assets. Up to 35 individuals will be selected to participate in the LC.

Program Overview and Activities

Six 90-minute virtual learning sessions between February and July 2027, including:

- A presentation from a subject matter expert(s)
- Opportunities to share local challenges, practices, and lessons with other participants through facilitated discussion
- Light activities between sessions — for example, interim reading, reflection prompts — to support application of learning
- Pre- and post-program surveys to assess learning and inform future training and technical assistance

Schedule and Time Commitment

Selected participants should be available for all core program activities. The anticipated commitment is two hours per month, including 90-minute virtual sessions the second Monday of the month from 1:30-3 p.m. ET and light activities/work between sessions starting in February 2027. Please note that topics and date and time are subject to change.

Activity	Date and Time
Session 1: Biomechanics of Overamping, Cocaine Overdose, and Methamphetamine Overdose	Monday, Feb. 8, 1:30-3 p.m. ET
Session 2: Polysubstance Use and Fentanyl	Monday, March 8, 1:30-3
Session 3: Understanding Drivers of Stimulant Overdose	Monday, April 12, 1:30-3 p.m. ET

Session 4: Evidence-Based Practices for Stimulant	Monday, May 10, 1:30-3
Session 5: The Changing Landscape of Stimulant Use in Rural Settings	Monday, June 14, 1:30-3 p.m. ET
Session 6: The Role of Primary Care and Emergency	Monday, July 12, 1:30-3

Application Submission

Applications are due by **11:59 p.m. ET on Friday, Dec. 11, 2026**, and must be submitted online **using this survey monkey link**.

Applicants will be notified of selection decisions the week of **Jan. 4, 2027**.

Questions about the application or program? Contact Jasmine Feng at JasmineF@TheNationalCouncil.org.

References

Tanz, L. J., Miller, K. D., Dinwiddie, A. T., Gladden, R. M., Asher, A., Baldwin, G., Nesbit, B., & O'Donnell, J. (2025, August 28). Drug overdose deaths involving stimulants — United States, January 2018–June 2024. *Morbidity and Mortality Weekly Report, 74*(32), 491–499. http://dx.doi.org/10.15585/mmwr.mm7432a1

Application Form Questions

*For reference only. Do not complete and submit this document. Final applications must be submitted through the **online form**.*

Applicant Information

Provide the following information about yourself and your organization.

1. Full Name
2. Job Title/Role
3. Brief description of your job: _____
4. Email
5. Phone
6. Organization or agency name
7. Physical address
8. Organization or agency type (select all that apply):
    - ☐ State health department
    - ☐ Local health department
    - ☐ Territorial health department
    - ☐ Tribal health department or Tribal organization
    - ☐ Community-based organization (CBO)
    - ☐ Community behavioral health organization (CBHO)
    - ☐ Certified Community Behavioral Health Clinic (CCBHC)
    - ☐ Health care organization or health system
    - ☐ Primary care organization
    - ☐ Emergency department or hospital
    - ☐ Overdose prevention organization
    - ☐ Other: _____
9. Select your U.S. Department of Health and Human Services region:
    - ☐ Region I: CT, ME, MA, NH, RI, VT
    - ☐ Region II: NJ, NY, Puerto Rico, U.S. Virgin Islands
    - ☐ Region III: DE, DC, MD, PA, VA, WV
    - ☐ Region IV: AL, FL, GA, KY, MS, NC, SC, TN
    - ☐ Region V: IL, IN, MI, MN, OH, WI

- ☐ Region VI: AR, LA, NM, OK, TX
- ☐ Region VII: IA, KS, MO, NE
- ☐ Region VIII: CO, MT, ND, SD, UT, WY
- ☐ Region IX: AZ, CA, HI, NV, and U.S.-affiliated Pacific jurisdictions
- ☐ Region X: AK, ID, OR, WA

10 What geographic area, populations, and communities does your organization primarily serve?

11 Describe your work with people who use stimulants.

Interest in the Program

1 Why are you interested in participating in the Stimulant Overdose Learning Community?

2 What are the most significant challenges or barriers your organization faces in preventing or responding to stimulant-involved overdose?

3 What do you hope to accomplish as a result of participating?

4 What types of applied learning do you find most effective for you (e.g., working with a partner, participating in small-group breakout sessions, completing worksheets, or engaging in individual reflection and exercises)?

Needs Assessment and Topical Interests

Optional: *Briefly describe what you want to learn or discuss about the following topics related to stimulant overdose.*

Topic	What would you like to learn
Overamping, cocaine overdose, and methamphetamine overdose	
Acute and chronic cardiovascular health	
Polysubstance use and fentanyl contamination	

Intentional and unintentional stimulant-	
Stimulant use and overdose in rural settings	
Drivers of stimulant overdose and	
Evidence-based practices for stimulant use management	
Contingency management and	
Primary care and emergency department roles	
Engaging people who use stimulants	
Linkage to and retention in care	
Other: _____	

Participation and Logistics Checklist

By submitting this application, the applicant confirms that they will:

- Participate in all virtual learning sessions:
  - Session 1: Monday, Feb. 8, 2027 | 1:30-3 p.m. ET
  - Session 2: Monday, March 8, 2027 | 1:30-3 p.m. ET
  - Session 3: Monday, April 12, 2027 | 1:30-3 p.m. ET
  - Session 4: Monday, May 10, 2027 | 1:30-3 p.m. ET
  - Session 5: Monday, June 14, 2027 | 1:30-3 p.m. ET
  - Session 6: Monday, July 12, 2027 | 1:30-3 p.m. ET
- Engage actively in facilitated large- and small-group discussions.
- Complete brief activities and surveys before, during, or after the program.
- Share relevant experiences while respecting privacy and confidentiality.
- Identify practical opportunities to apply learning within their organization or community.
- Notify program staff promptly if their availability changes.

Checklist

1 Do you agree to these participation expectations?

- ☐ Yes
- ☐ No

2 I agree and am available to participate in all virtual learning sessions:

- ☐ Session 1: Monday, Feb. 8, 2027 | 1:30-3 p.m. ET
- ☐ Session 2: Monday, March 8, 2027 | 1:30-3 p.m. ET
- ☐ Session 3: Monday, April 12, 2027 | 1:30-3 p.m. ET
- ☐ Session 4: Monday, May 10, 2027 | 1:30-3 p.m. ET
- ☐ Session 5: Monday, June 14, 2027 | 1:30-3 p.m. ET
- ☐ Session 6: Monday, July 12, 2027 | 1:30-3 p.m. ET

3 Are there accommodations, accessibility supports, or language access needs that would help you participate fully? If yes, please describe.

4 May program staff contact you with follow-up questions about this application?

- ☐ Yes
- ☐ No

5 Applicant certification: I certify that the information provided is accurate and understand that participation is on an individual basis and that no honorarium or stipend will be provided.

Full name: _____

Signature/confirmation: _____

Date: _____

This project is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $400,000 with 100% funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, CDC/HHS or the U.S. government.